Non-[18F]FDG PET in clinical oncology

被引：92

作者：

Groves, Ashley M. ^{[1
]}

Win, Thida

Ben Haim, Simona

Ell, Peter J.

机构：

[1] UCL, Inst Nucl Med, London NW1 2BU, England

[2] Lister Hosp, Stevenage, Herts, England

来源：

LANCET ONCOLOGY | 2007年 / 8卷 / 09期

关键词：

D O I：

10.1016/S1470-2045(07)70274-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PET is an exquisitely sensitive molecular imaging technique using positron-emitting radioisotopes coupled to specific ligands. Many biological targets of great interest can be imaged with these radiolabelled ligands. This review describes the current status of non-18-fluorodeoxyglucose PET tracers that have a potential clinical effect in oncology. With the help of these tracers, knowledge is being acquired on the molecular characterisation of specific tumours, their biological signature, and postinterventional response. The potential role of these imaging probes for tumour detection and monitoring is progressively being recognised by clinical oncologists, biologists, and pharmacologists.

引用

页码：822 / 830

页数：9

共 76 条

[21] [18F]FLT PET for diagnosis and staging of thoracic tumours [J].

Dittmann, H ;

Dohmen, BM ;

Paulsen, F ;

Eichhorn, K ;

Eschmann, SM ;

Horger, M ;

Wehrmann, M ;

Machulla, HJ ;

Bares, R .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (10) :1407-1412

[22] Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses:: a phase I trial [J].

Divgi, Chaitanya R. ;

Pandit-Taskar, Neeta ;

Jungbluth, Achim A. ;

Reuter, Victor E. ;

Gonen, Mithat ;

Ruan, Shutian ;

Pierre, Christine ;

Nagel, Andrew ;

Pryma, Daniel A. ;

Humm, John ;

Larson, Steven M. ;

Old, Lloyd J. ;

Russo, Paul .

LANCET ONCOLOGY, 2007, 8 (04) :304-310

[23] Evaluation of primary pulmonary carcinoid tumors using FDG PET [J].

Erasmus, JJ ;

McAdams, HP ;

Patz, EF ;

Coleman, RE ;

Ahuja, V ;

Goodman, PC .

AMERICAN JOURNAL OF ROENTGENOLOGY, 1998, 170 (05) :1369-1373

[24]

Eschmann SM, 2005, J NUCL MED, V46, P253

[25]

Even-Sapir E, 2006, J NUCL MED, V47, P287

[26] Is 11C-choline the most appropriate tracer for prostate cancer? [J].

Fazio, F ;

Picchio, M ;

Messa, C .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (05) :753-756

[27] Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma [J].

Floeth, Frank W. ;

Pauleit, Dirk ;

Sabel, Michael ;

Stoffels, Gabriele ;

Reifenberger, Guido ;

Riemenschneider, Markus J. ;

Jansen, Paul ;

Coenen, Heinz H. ;

Steiger, Hans-Jakob ;

Langen, Karl-Josef .

JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) :519-527

[28] Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy--glucose in positron emission tomography for colorectal cancer [J].

Francis, DL ;

Visvikis, D ;

Costa, DC ;

Arulampalam, THA ;

Townsend, C ;

Luthra, SK ;

Taylor, I ;

Ell, PJ .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (07) :988-994

[29] 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT [J].

Gabriel, Michael ;

Decristoforo, Clemens ;

Kendler, Dorota ;

Dobrozemsky, Georg ;

Heute, Dirk ;

Uprimny, Christian ;

Kovacs, Peter ;

Von Guggenberg, Elisabeth ;

Bale, Reto ;

Virgolini, Irene J. .

JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (04) :508-518

[30] Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors [J].

Ginj, Mihaela ;

Zhang, Hanwen ;

Waser, Beatrice ;

Cescato, Renzo ;

Wild, Damian ;

Wang, Xuejuan ;

Erchegyi, Judit ;

Rivier, Jean ;

Maecke, Helmut R. ;

Reubi, Jean Claude .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (44) :16436-16441

← 1 2 3 4 5 6 7 8 →